AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 231 min read$CRL

Parisotto Shannon M sold $743K of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 2,156 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $344.41 ($0.74M total) on 2026-10-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Oct 23, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

While the sale size is modest, it provides fresh data on insider sentiment.

02

Market read

The filing adds a new data point for investors monitoring insider activity at CRL.

03

What to watch

Potential upcoming earnings or strategic moves not disclosed.

Relevance 4/10Novelty 4/10Timing: after-hours filing on 2026-10-23

Background

Form 4 filings disclose insider transactions and are primary sources for such activity.

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

Officer Shannon M. Parisotto sold 2,156 shares of Charles River Laboratories for $743K via a Form 4 filing.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

C-level insider sold a sizable block at $344.41 per share; such sales often lead to short-term selling pressure.

Market effects

Sector

Minimal impact on the healthcare services sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory animal models and related services.

  • Individual
    Shannon M. Parisotto

    Chief Executive Vice President, Discovery & Safety Assessment.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min